Technical Analysis for VKTX - Viking Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 8.26 -10.99% -1.02
VKTX closed down 10.99 percent on Friday, March 22, 2019, on 1.34 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical VKTX trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 180 Bearish Setup Bearish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 22 Upper Bollinger Band Touch Strength 0.00%
Mar 21 Crossed Above 20 DMA Bullish -10.99%
Mar 21 Crossed Above 50 DMA Bullish -10.99%
Mar 21 MACD Bullish Centerline Cross Bullish -10.99%
Mar 21 180 Bullish Setup Bullish Swing Setup -10.99%

Older signals for VKTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which has completed Phase I trial for the treatment of cancer cachexia, a disease characterized by an uncontrolled decline in muscle mass. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as other preclinical programs for metabolic diseases and anemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Medicine Health Biopharmaceutical Cancer Medical Specialties Disease Diabetes Treatment Of Cancer Medication Anemia Metabolic Diseases Hepatitis Dyslipidemia Geriatrics Rehabilitation Medicine Lipid Disorders Cachexia Non Alcoholic Fatty Liver Disease Steatohepatitis
Is VKTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.0
52 Week Low 3.69
Average Volume 2,936,576
200-Day Moving Average 10.8175
50-Day Moving Average 8.3466
20-Day Moving Average 8.32
10-Day Moving Average 8.268
Average True Range 0.5852
ADX 17.67
+DI 24.4793
-DI 13.1015
Chandelier Exit (Long, 3 ATRs ) 7.614399999999999
Chandelier Exit (Short, 3 ATRs ) 9.1156
Upper Bollinger Band 9.1689
Lower Bollinger Band 7.4711
Percent B (%b) 0.46
BandWidth 20.40625
MACD Line 0.0094
MACD Signal Line -0.0565
MACD Histogram 0.0659
Fundamentals Value
Market Cap 228.78 Million
Num Shares 27.7 Million
EPS -0.83
Price-to-Earnings (P/E) Ratio -9.95
Price-to-Sales 0.00
Price-to-Book 10.84
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.78
Resistance 3 (R3) 9.94 9.60 9.52
Resistance 2 (R2) 9.60 9.21 9.52 9.44
Resistance 1 (R1) 8.93 8.98 8.76 8.77 9.35
Pivot Point 8.59 8.59 8.51 8.51 8.59
Support 1 (S1) 7.92 8.20 7.75 7.76 7.17
Support 2 (S2) 7.58 7.97 7.50 7.08
Support 3 (S3) 6.91 7.58 7.00
Support 4 (S4) 6.75